+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) - Drugs in Development, 2021

  • ID: 5473069
  • Report
  • October 2021
  • Region: Global
  • 815 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie Inc
  • Astex Pharmaceuticals Inc
  • Bio-Path Holdings Inc
  • Celularity Inc
  • ExCellThera Inc
  • Fate Therapeutics Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia - Drugs In Development, 2021, provides an overview of the Chronic Myelocytic Leukemia (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.

Report Highlights


This pipeline guide provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chronic Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 29, 19, 1, 1, 21, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 4, 5 and 4 molecules, respectively.

Chronic Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (Oncology)
  • The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Chronic Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (Oncology)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Astex Pharmaceuticals Inc
  • Bio-Path Holdings Inc
  • Celularity Inc
  • ExCellThera Inc
  • Fate Therapeutics Inc

Introduction
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones

Appendix
List of Tables
  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Arromax Pharmatech Co Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ascentage Pharma Group International, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Co, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celularity Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by CSPC Pharmaceutical Group Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Escend Pharmaceuticals Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eureka Therapeutics Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by ExCellThera Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Fate Therapeutics Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Fusion Pharma LLC, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlaxoSmithKline Plc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GT Biopharma Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Handa Pharmaceuticals Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Handa Pharmaceuticals LLC, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HEC Pharma Co Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Helocyte Biosciences Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HighPass Bio Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Housey Pharmaceutical Research Laboratories LLC, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by iCell Gene Therapeutics LLC, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by ImmunoForge Co Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by ImmunoGen Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by IN8bio Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corp, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Inhibikase Therapeutics Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Johnson & Johnson, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Kartos Therapeutics Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by MAA Laboratories Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Magenta Therapeutics Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mana Therapeutics Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by MedPacto Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Nanjing Sanhome Pharmaceutical Co Ltd, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, 2021
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc
  • Actinium Pharmaceuticals Inc
  • Arromax Pharmatech Co Ltd
  • Ascentage Pharma Group International
  • Astex Pharmaceuticals Inc
  • Bio-Path Holdings Inc
  • BioLineRx Ltd
  • Bristol-Myers Squibb Co
  • Celularity Inc
  • CSPC Pharmaceutical Group Ltd
  • Escend Pharmaceuticals Inc
  • Eureka Therapeutics Inc
  • ExCellThera Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Fusion Pharma LLC
Note: Product cover images may vary from those shown